<p>Tevogen Bio Holdings Inc.（纳斯达克代码：TVGN - 获取免费报告）在周三的交易中下跌了 6.4%。该公司的股价最低曾达到 0.3084 美元，最后交易价为 0.3172 美元。当天交易了约 486,137 股，较平均每日交易量 529,920 股下降了 8%。该股票此前收盘价为 0.3390 美元。</p>
<h2>分析师评级调整</h2>
<p>几家研究公司最近对 TVGN 进行了评估。Weiss Ratings 在 1 月 21 日的报告中重申了对 Tevogen Bio 股票的 “卖出（e+）” 评级。D. Boral Capital 在 11 月 20 日的研究报告中将 Tevogen Bio 的目标股价从 10.00 美元下调至 5.00 美元，并对该股票给予 “买入” 评级。一位投资分析师对该股票给予了买入评级，而另一位则给予了卖出评级。根据 MarketBeat.com 的数据，Tevogen Bio 的平均评级为 “持有”，平均目标价格为 5.00 美元。</p>
<p><strong>阅读我们对 Tevogen Bio 的最新股票分析</strong></p>
<h2>Tevogen Bio 股票表现</h2>
<p>该公司的 50 日移动平均线为 0.38 美元，200 日移动平均线为 0.67 美元。该股票的市值为 6302 万美元，市盈率为-1.67，贝塔值为-0.79。</p>
<p>Tevogen Bio（纳斯达克代码：TVGN - 获取免费报告）最近于 11 月 14 日发布了季度财报。该公司报告季度每股收益（EPS）为-0.03 美元，超出分析师一致预期的-0.06 美元，超出幅度为 0.03 美元。</p>
<h2>Tevogen Bio 的机构交易</h2>
<p>一家对冲基金最近增加了对 Tevogen Bio 股票的持股。Bridgeway Capital Management LLC 在第三季度将其在 Tevogen Bio Holdings Inc.（纳斯达克代码：TVGN - 免费报告）的持股比例提高了 66.7%，根据该公司最近向 SEC 提交的文件显示。该公司在季度内购买了额外的 33,000 股后，持有 82,500 股 Tevogen Bio 的股票。根据其最近向 SEC 提交的文件，Bridgeway Capital Management LLC 在 Tevogen Bio 的持股价值为 65,000 美元。</p>
<h2>Tevogen Bio 公司简介</h2>
<p>（获取免费报告）</p>
<p>Tevogen Bio plc（纳斯达克代码：TVGN）是一家临床阶段的生物技术公司，专注于开发针对肿瘤和严重病毒疾病的个性化自然杀伤（NK）细胞免疫疗法。Tevogen Bio 利用专有的诱导多能干细胞（iPSC）和供体来源的 NK 细胞平台，旨在创造可随时使用的细胞治疗产品，提供可扩展和成本效益高的治疗选择。该公司的主要候选药物 TVGN-484 是一种针对复发或难治性急性髓性白血病（AML）的同种异体 NK 细胞疗法，目前正在进行临床试验。</p>
<p>除了在 AML 的主要项目外，Tevogen Bio 的产品管线还包括针对血液恶性肿瘤、实体肿瘤和病毒感染的临床前 NK 细胞候选药物。</p>
<h2>精选故事</h2>
<ul>
<li>五只我们更看好的股票，胜过 Tevogen Bio</li>
<li>家族信托如何帮助保护您的财富</li>
<li>请勿删除，立即阅读</li>
<li>新法律：国会批准数字美元的设立？</li>
<li>用这四个简单步骤 “防止美联储影响” 您的银行账户</li>
<li>一项价值数万亿的美国 “出生权” 索赔 - 静悄悄地激活</li>
</ul>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
<h2>您现在应该投资 1,000 美元于 Tevogen Bio 吗？</h2>
<p>在您考虑 Tevogen Bio 之前，您需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前立即购买……而 Tevogen Bio 并不在名单上。</p>
<p>虽然 Tevogen Bio 目前在分析师中获得了持有评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

TVGNW

生物科技 ETF - VanEck Vectors

TVGN

动态生物技术与基因组 ETF - Invesco

纳斯达克生物科技指数 ETF - iShares Nasdaq

纽交所高增长板生物技术指数 ETF - First Trust

IBBQ

标普生物技术 3 倍做空 - Direxion

标普生物技术 ETF - SPDR

<p>Tevogen Bio（纳斯达克代码：TVGN）股价在交易中下跌 6.4%，至 0.3172 美元，交易量较平均水平下降 8%。分析师的评级不一，Weiss Ratings 维持 “卖出” 评级，而 D. Boral Capital 则将目标价从 10 美元下调至 5 美元，并给予 “买入” 评级。该股票的市值为 6302 万美元，市盈率为-1.67。Tevogen Bio 专注于开发针对癌症和病毒性疾病的 NK 细胞免疫疗法，其主要候选药物正在进行急性髓性白血病（AML）的临床试验</p>

<p>Tevogen Bio Holdings Inc. (NASDAQ:TVGN - Get Free Report) dropped 6.4% during trading on Wednesday . The company traded as low as $0.3084 and last traded at $0.3172. Approximately 486,137 shares were traded during trading, a decline of 8% from the average daily volume of 529,920 shares. The stock had previously closed at $0.3390.</p>
<div class="lb-trans"><p>Tevogen Bio Holdings Inc.（纳斯达克代码：TVGN - 获取免费报告）在周三的交易中下跌了 6.4%。该公司的股价最低曾达到 0.3084 美元，最后交易价为 0.3172 美元。当天交易了约 486,137 股，较平均每日交易量 529,920 股下降了 8%。该股票此前收盘价为 0.3390 美元。</p>
</div><h2>Analyst Upgrades and Downgrades</h2>
<div class="lb-trans"><h2>分析师评级调整</h2>
</div><p>Several research firms recently weighed in on TVGN. Weiss Ratings restated a &#34;sell (e+)&#34; rating on shares of Tevogen Bio in a report on Wednesday, January 21st. D. Boral Capital dropped their price target on shares of Tevogen Bio from $10.00 to $5.00 and set a &#34;buy&#34; rating on the stock in a research report on Thursday, November 20th. One investment analyst has rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, Tevogen Bio has an average rating of &#34;Hold&#34; and an average target price of $5.00.</p>
<div class="lb-trans"><p>几家研究公司最近对 TVGN 进行了评估。Weiss Ratings 在 1 月 21 日的报告中重申了对 Tevogen Bio 股票的 “卖出（e+）” 评级。D. Boral Capital 在 11 月 20 日的研究报告中将 Tevogen Bio 的目标股价从 10.00 美元下调至 5.00 美元，并对该股票给予 “买入” 评级。一位投资分析师对该股票给予了买入评级，而另一位则给予了卖出评级。根据 MarketBeat.com 的数据，Tevogen Bio 的平均评级为 “持有”，平均目标价格为 5.00 美元。</p>
</div><p><strong>Read Our Latest Stock Analysis on Tevogen Bio</strong></p>
<div class="lb-trans"><p><strong>阅读我们对 Tevogen Bio 的最新股票分析</strong></p>
</div><h2>Tevogen Bio Stock Performance</h2>
<div class="lb-trans"><h2>Tevogen Bio 股票表现</h2>
</div><p>The firm has a 50 day moving average of $0.38 and a two-hundred day moving average of $0.67. The stock has a market cap of $63.02 million, a P/E ratio of -1.67 and a beta of -0.79.</p>
<div class="lb-trans"><p>该公司的 50 日移动平均线为 0.38 美元，200 日移动平均线为 0.67 美元。该股票的市值为 6302 万美元，市盈率为-1.67，贝塔值为-0.79。</p>
</div><p>Tevogen Bio (NASDAQ:TVGN - Get Free Report) last issued its quarterly earnings results on Friday, November 14th. The company reported ($0.03) EPS for the quarter, topping analysts' consensus estimates of ($0.06) by $0.03.</p>
<div class="lb-trans"><p>Tevogen Bio（纳斯达克代码：TVGN - 获取免费报告）最近于 11 月 14 日发布了季度财报。该公司报告季度每股收益（EPS）为-0.03 美元，超出分析师一致预期的-0.06 美元，超出幅度为 0.03 美元。</p>
</div><h2>Institutional Trading of Tevogen Bio</h2>
<div class="lb-trans"><h2>Tevogen Bio 的机构交易</h2>
</div><p>A hedge fund recently raised its stake in Tevogen Bio stock. Bridgeway Capital Management LLC raised its stake in shares of Tevogen Bio Holdings Inc. (NASDAQ:TVGN - Free Report) by 66.7% during the 3rd quarter, according to the company in its most recent filing with the SEC. The firm owned 82,500 shares of the company's stock after purchasing an additional 33,000 shares during the quarter. Bridgeway Capital Management LLC's holdings in Tevogen Bio were worth $65,000 as of its most recent filing with the SEC.</p>
<div class="lb-trans"><p>一家对冲基金最近增加了对 Tevogen Bio 股票的持股。Bridgeway Capital Management LLC 在第三季度将其在 Tevogen Bio Holdings Inc.（纳斯达克代码：TVGN - 免费报告）的持股比例提高了 66.7%，根据该公司最近向 SEC 提交的文件显示。该公司在季度内购买了额外的 33,000 股后，持有 82,500 股 Tevogen Bio 的股票。根据其最近向 SEC 提交的文件，Bridgeway Capital Management LLC 在 Tevogen Bio 的持股价值为 65,000 美元。</p>
</div><h2>Tevogen Bio Company Profile</h2>
<div class="lb-trans"><h2>Tevogen Bio 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Tevogen Bio plc NASDAQ: TVGN is a clinical-stage biotechnology company focused on developing personalized natural killer (NK) cell immunotherapies for oncology and severe viral diseases. Leveraging proprietary induced pluripotent stem cell (iPSC) and donor-derived NK cell platforms, Tevogen Bio aims to create off-the-shelf cell therapy products that offer scalable and cost-efficient treatment options. The company's lead candidate, TVGN-484, is an allogeneic NK cell therapy in clinical trials for relapsed or refractory acute myeloid leukemia (AML).</p>
<div class="lb-trans"><p>Tevogen Bio plc（纳斯达克代码：TVGN）是一家临床阶段的生物技术公司，专注于开发针对肿瘤和严重病毒疾病的个性化自然杀伤（NK）细胞免疫疗法。Tevogen Bio 利用专有的诱导多能干细胞（iPSC）和供体来源的 NK 细胞平台，旨在创造可随时使用的细胞治疗产品，提供可扩展和成本效益高的治疗选择。该公司的主要候选药物 TVGN-484 是一种针对复发或难治性急性髓性白血病（AML）的同种异体 NK 细胞疗法，目前正在进行临床试验。</p>
</div><p>In addition to its lead program in AML, Tevogen Bio's pipeline includes preclinical NK cell candidates directed against hematological malignancies, solid tumors and viral infections.</p>
<div class="lb-trans"><p>除了在 AML 的主要项目外，Tevogen Bio 的产品管线还包括针对血液恶性肿瘤、实体肿瘤和病毒感染的临床前 NK 细胞候选药物。</p>
</div><h2>Featured Stories</h2>
<div class="lb-trans"><h2>精选故事</h2>
</div><ul>
<li>Five stocks we like better than Tevogen Bio</li>
<li>How a Family Trust May Be Able To Help Preserve Your Wealth</li>
<li>Do not delete, read immediately</li>
<li>NEW LAW: Congress Approves Setup For Digital Dollar?</li>
<li>“Fed Proof” Your Bank Account with THESE 4 Simple Steps</li>
<li>A U.S. “birthright” claim worth trillions - activated quietly</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票，胜过 Tevogen Bio</li>
<li>家族信托如何帮助保护您的财富</li>
<li>请勿删除，立即阅读</li>
<li>新法律：国会批准数字美元的设立？</li>
<li>用这四个简单步骤 “防止美联储影响” 您的银行账户</li>
<li>一项价值数万亿的美国 “出生权” 索赔 - 静悄悄地激活</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Tevogen Bio Right Now?</h2>
<div class="lb-trans"><h2>您现在应该投资 1,000 美元于 Tevogen Bio 吗？</h2>
</div><p>Before you consider Tevogen Bio, you'll want to hear this.</p>
<div class="lb-trans"><p>在您考虑 Tevogen Bio 之前，您需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Tevogen Bio wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前立即购买……而 Tevogen Bio 并不在名单上。</p>
</div><p>While Tevogen Bio currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Tevogen Bio 目前在分析师中获得了持有评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Tevogen Bio（NASDAQ:TVGN）股价下跌 6.4% - 以下是原因